- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Morepen Laboratories has announced a board meeting outcome approving the audited consolidated financial results for the quarter and financial year ended March 31, 2025. The group posted revenue of Rs. 465.85 Cr and a net profit of Rs. 118.02 Cr, showing solid growth. The Board approved a final dividend of Rs. 0.20 per share, pending shareholder nod. Strategic moves include reducing its stake in Dr. Morepen Ltd. to 80% after warrant conversion, acquiring 80% of Quick Med Private Limited (pharma distribution), and launching a wholly owned medical device subsidiary in Dubai. New auditors appointed for FY26 include M/s. Vijender Sharma & Co. and M/s. Harvinder & Associates.